DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRX) in a research report sent to investors on Thursday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

DURECT Stock Performance

Shares of NASDAQ DRRX opened at $0.81 on Thursday. DURECT has a fifty-two week low of $0.70 and a fifty-two week high of $1.88. The company has a market cap of $25.02 million, a PE ratio of -1.32 and a beta of 0.91. The business has a 50-day simple moving average of $0.80 and a two-hundred day simple moving average of $1.01.

DURECT (NASDAQ:DRRX) last released its earnings results on Wednesday, March 26th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.12). DURECT had a negative return on equity of 300.62% and a negative net margin of 198.58%. The company had revenue of $2.30 million during the quarter, compared to analyst estimates of $6.91 million. On average, sell-side analysts predict that DURECT will post -0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DURECT

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Richmond Brothers Inc. increased its holdings in shares of DURECT by 12.2% in the fourth quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock valued at $961,000 after purchasing an additional 138,920 shares during the period. Geode Capital Management LLC lifted its holdings in shares of DURECT by 4.8% during the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 14,658 shares during the period. Finally, Jane Street Group LLC boosted its position in DURECT by 266.0% in the fourth quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 28,486 shares during the last quarter. Hedge funds and other institutional investors own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.